The microbial contract biomanufacturing market is projected to be worth USD 9.3 billion by 2030.
The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment     London   Roots Analysis has announced the addition of the “Microbial Contract Biomanufacturing Market, 2020-2030”...
0 Comments 0 Shares